Skip to main content
Premium Trial:

Request an Annual Quote

A Startup is Born

Premium

Ever wonder how many business ideas and new partnerships could trace their genesis back to TIGR’s annual genomics conference? When a lightbulb went on this year, the originators of a bright idea wasted no time. The four founders of DysFunctional Genomics (see photo) pulled together a senior management team and launched a public relations campaign before they left Miami.

 

Chief Operating Officer

Doug Bigwood

(nee: Bioinformatics Director, Bayer)

 

Says strategy is to conduct expression profiling to determine differential between functional and dysfunctional humans. Gambling that “underlying molecular basis of dysfunctionality will provide clues about genome-industry behavior.”

Corporate Communications Director Steve Lincoln

(nee: VP.Bioinformatics R&D, Incyte Genomics)

 

Says he’s cutting and pasting from business plans of “existing dysfunctional genomics companies and using a lot of 50-cent words.”

Marketing Director, Roger Wiegand

(nee: VP Technology Acquisition, Cereon Genomics)

 

Admits business plan is “still a bit sketchy.” Can’t recall marketing strategy — “you’ve caught me a bit flatfooted.” Estimates need for $100 million in startup capital. Says venture “absolutely” aspires to go public.

Chief Scientific Officer, Dave Schubring

(nee: Sr. Systems Administrator, Incyte Genomics)

 

Not available for comment. COO Bigwood says, “Dave has no idea what we’re talking about. He’s really the computer guy.”

Operations Director, Chris Marcazzo

(nee: Product Marketing Director, Lion Bioscience)

 

Will oversee Falkland Islands and Cuzco, Peru facilities. According to business plan: “Sheep are useful model organism for studies of genomic-industry investor behavior.”

Chairman, Todd Smith

(nee: President, Geospiza)

 

Explains choice to finance startup with his credit card: “I don’t know these people. I was recruited by the communications guy. But they’re a top-notch team with a proven track record.” Will measure company’s success by quality of freebies it distributes at GSAC 2001.

 

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.